BackScopus Biopharma Overview
Scopus Biopharma Inc

Scopus Biopharma Discounted Cash Flow

Is SCPS undervalued? Intrinsic value estimate stands at $0.0059.

Get informed when a big investor buys or sells

+ Follow

Fair Value

$0.01

Current Fair Value

$0.01
↑ 1375.0% Upside

Undervalued by 1375.0% based on the discounted cash flow analysis.

Average Upside/Downside (Comparison Companies)

Loading

Fair Value vs. Stock Price History

Loading

Upside/Downside History

Loading

Upside/Downside Comparison

Loading

Scopus Biopharma (SCPS) FAQ

Scopus Biopharma (SCPS) currently reports a DCF fair value of $0.0059. Use the charts on this page to explore Scopus Biopharma's DCF fair value history and peer comparisons.

Scopus Biopharma's discounted cash flow (DCF) fair value estimate is $0.0059, about 1375.0% undervalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.

Start with the current DCF fair value of $0.0059, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Scopus Biopharma, and consider following SCPS for alerts when major investors trade the stock.

Scopus Biopharma is classified in the Healthcare sector. On DCF fair value, it currently shows $0.0059. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SCPS with unrelated industries.